A Phase 1/2 interventional study of Abiraterone acetate and Abiraterone acetate in Prostate Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 43rd largest by enrollment, is one of 2 that started in 2006, is one of 8 in phase 1/2, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 67 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 56 across the 98 interventional studies. Of the 60 that completed or were terminated, 40 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 37th largest by enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2006, is one of 4 in phase 1/2, and was the 5th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
8 of the studies testing Abiraterone Acetate in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
| NCT01786265M.D. Anderson Cancer CenterFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | 2027-02-01 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
This is an open-label (identity of assigned study drug will be known) study to evaluate the safety, pharmacokinetics (study of what the body does to a drug), pharmacodynamics (study of what a drug does to the body), and anti-tumor activities of abiraterone acetate (also known as CB7630) in patients with HRPC. The study will be conducted in 2 phases (Phase 1 and Phase 2). In the first part of the study (Phase 1), the maximum tolerated dose (MTD) of abiraterone acetate will be determined for use in the second part of the study (Phase 2) where the number of patients who achieve at least a 50% decrease in prostate specific antigen (PSA) during treatment with abiraterone acetate will be assessed (MTD from Phase 1). Abiraterone acetate will be taken orally (by mouth) in fed and fasted patients once daily. Doses of abiraterone acetate (starting at 250 mg up to a maximum of 2000 mg) will be taken for 28-day treatment periods to determine the MTD. Patients will take MTD of abiraterone acetate for up to twelve 28 day cycles (12 months; patients will be given the option of staying on abiraterone acetate treatment if they are deriving benefit). In Phase 2, prednisone or dexamethasone will be administered concurrently with abiraterone acetate. Serial pharmacokinetic and pharmacodynamic samples will be collected and safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1
Phase 2
Exclusion Criteria:
Phase 1
Phase 2
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abiraterone acetate
Drug: Abiraterone acetate · Drug: prednisone/prednisolone or dexamethasone
The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
Phase 1: Maximum Tolerated Dose (MTD) of Abiraterone Acetate
The MTD is the highest dose of a drug or treatment that does not cause unacceptable side effects.
Time frame: Up to Cycle 12
Phase 2: Participants With Greater Than or Equal to 50 Percent Decline in Prostate Specific Antigen (PSA)
Number of participants with greater than or equal to 50 percent decrease in PSA levels were assessed. PSA decline was evaluated according to (Prostate Specific Antigen Working Group) PSAWG criteria. Decrease in PSA levels represented improvement.
Time frame: Up to 12 weeks from start of treatment
Phase 1: Maximum Plasma Concentration (Cmax) of Abiraterone Acetate
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3.
Phase 1: Time to Reach the Maximum Plasma Concentration (Tmax) of Abiraterone Acetate
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose)
Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Phase 1: Area Under the Plasma-Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Abiraterone Acetate
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Phase 1: Area Under the Plasma-Concentration-time Curve From Time 0 to Infinite Time (AUCINF_obs) of Abiraterone Acetate
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Phase 1: Terminal Half-life (HL_Lambda_z) of Abiraterone Acetate
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Phase 1: Total Body Clearance (Cl_F_obs) of Abiraterone Acetate
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Phase 1: Volume of Distribution (Vz_F_obs) of Abiraterone Acetate
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Volume of distribution is normally calculated by using equation volume of distribution =dose/initial concentration. Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Phase 2: Radiographic Progression Free Survival (RAD-PFS)
RAD-PFS is the time interval from the date of first dose of abiraterone acetate therapy to the date of death or radiographic disease progression according to the RECIST (Response Evaluation Criteria In Solid Tumors) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 12 weeks from start of treatment
Phase 2: PSA Progression Free Survival (PSA-PFS)
PSA-PFS is the time interval from the date of first dose of abiraterone acetate therapy to the date of death or the PSA progression as defined by the Prostate Specific Antigen Working Group (PSAWG) criteria.
Time frame: Up to 12 weeks from start of treatment
Phase 2: Radiographic Objective Response Rate (RAD-ORR)
The objective response rate is defined as the proportion of participants with measurable lesions achieving a Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 12 weeks from start of treatment
Phase 2: Time to PSA Progression
The time interval from the date of first dose of abiraterone acetate therapy to the date of the PSA progression as defined by the PSAWG criteria.
Time frame: Up to 12 weeks from start of treatment
Phase 2: Duration of PSA Response
Duration of PSA response was defined as the duration between the date of confirmed PSA response and subsequent PSA progression date as defined by the PSAWG criteria.
Time frame: Up to 12 weeks from start of treatment
Phase 2: Participants With Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score
ECOG performance status score ranges from 0 to 5 where 0=fully active, perform all pre-disease activities without restriction. 1=restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2=ambulatory, capable of self-care, unable to carry out any work activities, up and about more than (\>) 50% of waking hours. 3=capable of limited self-care, confined to bed or chair \>50% of waking hours. 4=completely disabled, not capable of any self-care, totally confined to bed or chair. 5=dead.
Time frame: Up to 12 weeks from start of treatment
Phase 2: Overall Survival
Overall survival is the time interval from the date of first dose (cycle 1 day 1) of abiraterone acetate therapy to the date of death from any cause.
Time frame: Up to Month 60
Phase 2: Duration of Objective Response
Duration of objective response was assessed only in participants who achieved a CR or PR, and measured from the first documented date of response to the first documented date of disease progression according to the RECIST criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 12 weeks from start of treatment
The study was conducted between 10 July 2006 and 22 December 2012.
| Milestone | Phase 1 250 MG/DAY | Phase 1 500 MG/DAY | Phase 1 750 MG/DAY | Phase 1 1000 MG/DAY | Phase 2 1000 MG/DAY |
|---|---|---|---|---|---|
| Started | 6 | 9 | 6 | 12 | 0 |
| Completed | 0 | 0 | 0 | 2 | 0 |
| Not completed | 6 | 9 | 6 | 10 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 5 | 6 | 6 | 10 | 0 |
| Withdrew: Symptomatic deterioration | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 1 | 0 | 0 | 0 |
| Milestone | Phase 1 250 MG/DAY | Phase 1 500 MG/DAY | Phase 1 750 MG/DAY | Phase 1 1000 MG/DAY | Phase 2 1000 MG/DAY |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 33 |
| Completed | 0 | 0 | 0 | 0 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 27 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 20 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 3 |
The MTD is the highest dose of a drug or treatment that does not cause unacceptable side effects.
| mg/day | Phase I Dose Escalation |
|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) of Abiraterone Acetate | NA ± 0 |
Number of participants with greater than or equal to 50 percent decrease in PSA levels were assessed. PSA decline was evaluated according to (Prostate Specific Antigen Working Group) PSAWG criteria. Decrease in PSA levels represented improvement.
| participants | Phase II Dose Treatment |
|---|---|
| Confirmed | 26 |
| Not Confirmed | 2 |
| Total | 28 |
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
| nanomoles per liter (nmol/L) | Phase I Dose Escalation (250mg) | Phase I Dose Escalation (500mg) | Phase I Dose Escalation (750mg) | Phase I Dose Escalation (1000mg) |
|---|---|---|---|---|
| Fasted | 283.000 ± 142.265 | 330.633 ± 204.889 | 289.533 ± 126.646 | 509.500 ± 366.452 |
| Fed | 421.000 ± 75.809 | 676.000 ± 147.866 | 1552.000 ± 458.082 | 2194.250 ± 1096.914 |
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose)
| hour (hr) | Phase I Dose Escalation (250mg) | Phase I Dose Escalation (500mg) | Phase I Dose Escalation (750mg) | Phase I Dose Escalation (1000mg) |
|---|---|---|---|---|
| Fasted | 2.000 ± 0.000 | 1.500 ± 0.548 | 2.033 ± 0.058 | 1.833 ± 0.408 |
| Fed | 2.044 ± 0.077 | 2.667 ± 1.155 | 2.000 ± 0.000 | 4.000 ± 0.000 |
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
| hr*nmol/L | Phase I Dose Escalation (250mg) | Phase I Dose Escalation (500mg) | Phase I Dose Escalation (750mg) | Phase I Dose Escalation (1000mg) |
|---|---|---|---|---|
| Fasted | 1329.178 ± 699.977 | 1625.059 ± 930.364 | 1565.659 ± 661.289 | 3039.937 ± 1902.697 |
| Fed | 1310.715 ± 311.041 | 3624.781 ± 1041.927 | 8920.790 ± 3060.457 | 13695.482 ± 5623.185 |
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
| hr*nmol/L | Phase I Dose Escalation (250mg) | Phase I Dose Escalation (500mg) | Phase I Dose Escalation (750mg) | Phase I Dose Escalation (1000mg) |
|---|---|---|---|---|
| Fasted | 1411.268 ± 697.183 | 1781.374 ± 986.770 | 1665.454 ± 704.551 | 3478.385 ± 2012.176 |
| Fed | 1386.939 ± 290.240 | 3839.804 ± 1080.853 | 9358.743 ± 3338.601 | 14404.387 ± 5971.041 |
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
| hour (hr) | Phase I Dose Escalation (250mg) | Phase I Dose Escalation (500mg) | Phase I Dose Escalation (750mg) | Phase I Dose Escalation (1000mg) |
|---|---|---|---|---|
| Fasted | 5.284 ± 1.676 | 10.591 ± 6.337 | 7.066 ± 3.431 | 14.361 ± 7.655 |
| Fed | 5.125 ± 1.039 | 6.913 ± 5.720 | 7.939 ± 2.633 | 12.454 ± 1.218 |
Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
| liter per hour (l/hr) | Phase I Dose Escalation (250mg) | Phase I Dose Escalation (500mg) | Phase I Dose Escalation (750mg) | Phase I Dose Escalation (1000mg) |
|---|---|---|---|---|
| Fasted | 4288.456 ± 1319.322 | 5440.949 ± 4844.515 | 1518.748 ± 822.714 | 2649.954 ± 4617.049 |
| Fed | 529.606 ± 99.532 | 391.046 ± 99.118 | 246.643 ± 72.970 | 231.383 ± 97.746 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Volume of distribution is normally calculated by using equation volume of distribution =dose/initial concentration. Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).
| Liter (L) | Phase I Dose Escalation (250mg) | Phase I Dose Escalation (500mg) | Phase I Dose Escalation (750mg) | Phase I Dose Escalation (1000mg) |
|---|---|---|---|---|
| Fasted | 653.745 ± 447.316 | 10252.077 ± 12268.787 | 13688.367 ± 4265.429 | 25494.398 ± 18670.215 |
| Fed | 3940.400 ± 1275.408 | 3418.280 ± 1934.384 | 2739.655 ± 1084.694 | 4068.885 ± 1462.613 |
RAD-PFS is the time interval from the date of first dose of abiraterone acetate therapy to the date of death or radiographic disease progression according to the RECIST (Response Evaluation Criteria In Solid Tumors) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| days | Phase II Dose Treatment |
|---|---|
| Phase 2: Radiographic Progression Free Survival (RAD-PFS) | NA (NA to NA) |
PSA-PFS is the time interval from the date of first dose of abiraterone acetate therapy to the date of death or the PSA progression as defined by the Prostate Specific Antigen Working Group (PSAWG) criteria.
| days | Phase II Dose Treatment |
|---|---|
| Phase 2: PSA Progression Free Survival (PSA-PFS) | 473 (281 to NA) |
The objective response rate is defined as the proportion of participants with measurable lesions achieving a Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| participants | Phase II Dose Treatment |
|---|---|
| Confirmed | 9 (38.6 to 90.9) |
| Not Confirmed | 1 (0.2 to 36.0) |
The time interval from the date of first dose of abiraterone acetate therapy to the date of the PSA progression as defined by the PSAWG criteria.
| days | Phase II Dose Treatment |
|---|---|
| Phase 2: Time to PSA Progression | 497 (281 to NA) |
Duration of PSA response was defined as the duration between the date of confirmed PSA response and subsequent PSA progression date as defined by the PSAWG criteria.
| days | Phase II Dose Treatment |
|---|---|
| Phase 2: Duration of PSA Response | 477 (283 to NA) |
ECOG performance status score ranges from 0 to 5 where 0=fully active, perform all pre-disease activities without restriction. 1=restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2=ambulatory, capable of self-care, unable to carry out any work activities, up and about more than (\>) 50% of waking hours. 3=capable of limited self-care, confined to bed or chair \>50% of waking hours. 4=completely disabled, not capable of any self-care, totally confined to bed or chair. 5=dead.
| participants | Phase II Dose Treatment |
|---|---|
| Baseline ECOG 0 | 20 |
| Baseline ECOG 1 | 13 |
| Baseline ECOG 2 | 0 |
| Baseline ECOG 3 | 0 |
| Baseline ECOG 4 | 0 |
| Best Post-Baseline ECOG 0 | 28 |
| Best Post-Baseline ECOG 1 | 5 |
| Best Post-Baseline ECOG 2 | 0 |
| Best Post-Baseline ECOG 3 | 0 |
| Best Post-Baseline ECOG 4 | 0 |
Overall survival is the time interval from the date of first dose (cycle 1 day 1) of abiraterone acetate therapy to the date of death from any cause.
| days | Phase II Dose Treatment |
|---|---|
| Phase 2: Overall Survival | NA (NA to NA) |
Duration of objective response was assessed only in participants who achieved a CR or PR, and measured from the first documented date of response to the first documented date of disease progression according to the RECIST criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| days | Phase II Dose Treatment |
|---|---|
| Phase 2: Duration of Objective Response | NA (253 to NA) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 250 MG/DAY | — | 1/6 (16.7%) | 6/6 (100%) |
| Phase 1 500 MG/DAY | — | 2/9 (22.2%) | 9/9 (100%) |
| Phase 1 750 MG/DAY | — | 0/6 (0%) | 6/6 (100%) |
| Phase 1 1000 MG/DAY | — | 0/12 (0%) | 12/12 (100%) |
| Phase 2 1000 MG/DAY | — | 10/33 (30.3%) | 33/33 (100%) |
| Event | Phase 1 250 MG/DAY | Phase 1 500 MG/DAY | Phase 1 750 MG/DAY | Phase 1 1000 MG/DAY | Phase 2 1000 MG/DAY |
|---|---|---|---|---|---|
| SyncopeNervous system disorders | 1/6 | 1/9 | 0/6 | 0/12 | 1/33 |
| HypokalaemiaMetabolism and nutrition disorders | 0/6 | 1/9 | 0/6 | 0/12 | 1/33 |
| Urinary Tract InfectionInfections and infestations | 0/6 | 0/9 | 0/6 | 0/12 | 2/33 |
| UrosepsisInfections and infestations | 0/6 | 0/9 | 0/6 | 0/12 | 2/33 |
| HaematuriaRenal and urinary disorders | 0/6 | 0/9 | 0/6 | 0/12 | 2/33 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 0/9 | 0/6 | 0/12 | 1/33 |
| Arrhythmia SupraventricularCardiac disorders | 0/6 | 0/9 | 0/6 | 0/12 | 1/33 |
| Myocardial InfarctionCardiac disorders | 0/6 | 0/9 | 0/6 | 0/12 | 1/33 |
| Ventricular ExtrasystolesCardiac disorders | 0/6 | 0/9 | 0/6 | 0/12 | 1/33 |
| Oedema PeripheralGeneral disorders | 0/6 | 0/9 | 0/6 | 0/12 | 1/33 |
| Event | Phase 1 250 MG/DAY | Phase 1 500 MG/DAY | Phase 1 750 MG/DAY | Phase 1 1000 MG/DAY | Phase 2 1000 MG/DAY |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 3/6 | 7/9 | 4/6 | 8/12 | 16/33 |
| HypokalaemiaMetabolism and nutrition disorders | 0/6 | 1/9 | 4/6 | 4/12 | 10/33 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/6 | 2/9 | 4/6 | 1/12 | 5/33 |
| HeadacheNervous system disorders | 0/6 | 3/9 | 2/6 | 7/12 | 3/33 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 4/9 | 3/6 | 4/12 | 7/33 |
| NauseaGastrointestinal disorders | 1/6 | 3/9 | 1/6 | 6/12 | 5/33 |
| Oedema PeripheralGeneral disorders | 1/6 | 4/9 | 0/6 | 6/12 | 9/33 |
| HypertensionVascular disorders | 2/6 | 2/9 | 3/6 | 5/12 | 7/33 |
| Abdominal PainGastrointestinal disorders | 1/6 | 2/9 | 2/6 | 2/12 | 3/33 |
| ConstipationGastrointestinal disorders | 0/6 | 3/9 | 2/6 | 2/12 | 7/33 |
| Age, Continuous(years) | Phase 1 250 MG/DAY | Phase 1 500 MG/DAY | Phase 1 750 MG/DAY | Phase 1 1000 MG/DAY | Phase 2 1000 MG/DAY | Total |
|---|---|---|---|---|---|---|
| Mean | 66.7 ± 6.19 | 67.6 ± 6.5 | 73.2 ± 8.18 | 72.9 ± 8.3 | 70.3 ± 8.51 | 70.3 ± 8.05 |
| Sex: Female, Male(Participants) | Phase 1 250 MG/DAY | Phase 1 500 MG/DAY | Phase 1 750 MG/DAY | Phase 1 1000 MG/DAY | Phase 2 1000 MG/DAY | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 9 | 6 | 12 | 33 | 66 |
| Region of Enrollment(participants) | Phase 1 250 MG/DAY | Phase 1 500 MG/DAY | Phase 1 750 MG/DAY | Phase 1 1000 MG/DAY | Phase 2 1000 MG/DAY | Total |
|---|---|---|---|---|---|---|
| United States | 6 | 9 | 6 | 12 | 33 | 66 |
The record gives a start of Jun 2006, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abiraterone Acetate
Janssen Research & Development, LLC →